title: Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
abstract: Patients with relapsed/refractory hematologic malignancies after allogeneic stem cell transplantation have a poor prognosis due to the high rate of relapse. Techniques capable of decreasing post-transplantation relapse rates are urgently sought. This study aimed to explore the feasibility and safety of allogeneic hematopoietic stem cell transplantation (HSCT) following infusion of donor cytokine-induced killer (CIK) cells. CIK cells were generated in vitro from donor peripheral blood mononuclear cells, and were phenotyped using flow cytometric analysis. CIK cells were administered to 15 high-risk relapsed/refractory hematologic malignancy patients who were not in complete remission in multiple infusions. These patients also received allogeneic HSCT. The side effects and outcomes were recorded. All patients achieved engraftment and complete remission. After CIK cell infusion, two patients developed graft-versus-host disease (GvHD), which was controlled by additional immunosuppressant drugs. At the last follow-up, nine patients had died and six patients were surviving at a median follow-up of 1513days (range, 771-1655days). In conclusion, allogeneic HSCT combined with sequential infusion of donor CIK cells is well tolerated in salvage relapsed/refractory hematologic malignancy patients.
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Han-Qing
authors.initials: HQ
authors.lastname: Zeng
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China. Electronic address: sflou354cq@sina.com.
authors.forename: Shi-Feng
authors.initials: SF
authors.lastname: Lou
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Hematology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 40010, China.
authors.forename: Jian-Chuan
authors.initials: JC
authors.lastname: Deng
mesh_terms: D000293:Adolescent; D000328:Adult; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation*; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D017708:Leukocyte Transfusion / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016879:Salvage Therapy / Q000379:methods; D015996:Survival Rate; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
keywords: Allogeneic stem cell transplantation; Cytokine-induced killer cells; Graft versus host disease; Hematologic malignancy